Pharmacotherapy for Mood Disorders in Pregnancy: a Review of Pharmacokinetic Changes and Clinical Recommendations for Therapeutic Drug Monitoring

Overview

Journal J Clin Psychopharmacol

Specialty Pharmacology

Date 2014 Feb 15

PMID 24525634

Citations 42

Authors

Kristina M Deligiannidis

Nancy Byatt

Marlene P Freeman

Affiliations

Soon will be listed here.

Abstract

Objective: Pharmacotherapy for mood disorders during pregnancy is often complicated by pregnancy-related pharmacokinetic changes and the need for dose adjustments. The objectives of this review are to summarize the evidence for change in perinatal pharmacokinetics of commonly used pharmacotherapies for mood disorders, discuss the implications for clinical and therapeutic drug monitoring (TDM), and make clinical recommendations.

Methods: The English-language literature indexed on MEDLINE/PubMed was searched for original observational studies (controlled and uncontrolled, prospective and retrospective), case reports, and case series that evaluated or described pharmacokinetic changes or TDM during pregnancy or the postpartum period.

Results: Pregnancy-associated changes in absorption, distribution, metabolism, and elimination may result in lowered psychotropic drug levels and possible treatment effects, particularly in late pregnancy. Mechanisms include changes in both phase 1 hepatic cytochrome P450 and phase 2 uridine diphosphate glucuronosyltransferase enzyme activities, changes in hepatic and renal blood flow, and glomerular filtration rate. Therapeutic drug monitoring, in combination with clinical monitoring, is indicated for tricyclic antidepressants and mood stabilizers during the perinatal period.

Conclusions: Substantial pharmacokinetic changes can occur during pregnancy in a number of commonly used antidepressants and mood stabilizers. Dose increases may be indicated for antidepressants including citalopram, clomipramine, imipramine, fluoxetine, fluvoxamine, nortriptyline, paroxetine, and sertraline, especially late in pregnancy. Antenatal dose increases may also be needed for lithium, lamotrigine, and valproic acid because of perinatal changes in metabolism. Close clinical monitoring of perinatal mood disorders and TDM of tricyclic antidepressants and mood stabilizers are recommended.

Citing Articles

Changes in the pharmacokinetics of lurasidone in a pregnant woman with schizophrenia.

Kawai M, Aratake R, Ogawa T PCN Rep. 2024; 3(4):e70043.

PMID: 39659990 PMC: 11628732. DOI: 10.1002/pcn5.70043.

The Association of Antidepressants in Late Pregnancy with Postpartum Hemorrhage: Systematic Review of Controlled Observational Studies.

Bobo W, Moore K, Betcher H, Larish A, Stoppel C, VandeVoort J J Child Adolesc Psychopharmacol. 2024; 34(10):428-446.

PMID: 39453674 PMC: 11807859. DOI: 10.1089/cap.2024.0085.

Striking the Balance: Bipolar Disorder in the Perinatal Period.

Hasser C, Ameresekere M, Girgis C, Knapp J, Shah R Focus (Am Psychiatr Publ). 2024; 22(1):3-15.

PMID: 38694148 PMC: 11058914. DOI: 10.1176/appi.focus.20230020.

Depression Treatment in Pregnancy: Is It Safe, or Is It Not?.

Gallitelli V, Franco R, Guidi S, Puri L, Parasiliti M, Vidiri A Int J Environ Res Public Health. 2024; 21(4).

PMID: 38673317 PMC: 11049910. DOI: 10.3390/ijerph21040404.

Intersection of Sex and Depression: Pathogenesis, Presentation, and Treatments.

Frohman D, Nnah K, Tsirka S Handb Exp Pharmacol. 2023; 282:163-180.

PMID: 37439845 PMC: 11519624. DOI: 10.1007/164_2023_670.

References

Cox J, Holden J, Sagovsky R . Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987; 150:782-6. DOI: 10.1192/bjp.150.6.782. View

De Santis M, De Luca C, Mappa I, Cesari E, Quattrocchi T, Spagnuolo T . Antiepileptic drugs during pregnancy: pharmacokinetics and transplacental transfer. Curr Pharm Biotechnol. 2011; 12(5):781-8. DOI: 10.2174/138920111795470958. View

Greenblatt D, von Moltke L, Harmatz J, Shader R . Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol. 1999; 19(5 Suppl 1):23S-35S. DOI: 10.1097/00004714-199910001-00003. View

Keck Jr P, McElroy S . Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry. 2002; 63 Suppl 4:3-11. View

Ter Horst P, Jansman F, van Lingen R, Smit J, de Jong-van den Berg L, Brouwers J . Pharmacological aspects of neonatal antidepressant withdrawal. Obstet Gynecol Surv. 2008; 63(4):267-79. DOI: 10.1097/OGX.0b013e3181676be8. View

Freeman M, Nolan Jr P, Davis M, Anthony M, Fried K, Fankhauser M . Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol. 2008; 28(6):646-53. DOI: 10.1097/JCP.0b013e31818d2048. View

Devane C, Liston H, Markowitz J . Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002; 41(15):1247-66. DOI: 10.2165/00003088-200241150-00002. View

Worda C, Sator M, Schneeberger C, Jantschev T, Ferlitsch K, Huber J . Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. Hum Reprod. 2003; 18(2):262-6. DOI: 10.1093/humrep/deg059. View

Malhi G, Tanious M, Das P, Berk M . The science and practice of lithium therapy. Aust N Z J Psychiatry. 2012; 46(3):192-211. DOI: 10.1177/0004867412437346. View

10.

Lobo E, Loghin C, Knadler M, Quinlan T, Zhang L, Chappell J . Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. Clin Pharmacokinet. 2008; 47(2):103-9. DOI: 10.2165/00003088-200847020-00003. View

11.

Wisner K, Sit D, Hanusa B, Moses-Kolko E, Bogen D, Hunker D . Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009; 166(5):557-66. PMC: 4426499. DOI: 10.1176/appi.ajp.2008.08081170. View

12.

Tanaka T, Moretti M, Verjee Z, Shupak M, Ivanyi K, Ito S . A pitfall of measuring lithium levels in neonates. Ther Drug Monit. 2008; 30(6):752-4. DOI: 10.1097/FTD.0b013e3181898978. View

13.

KOERNER M, Yerby M, Friel P, McCormick K . Valproic acid disposition and protein binding in pregnancy. Ther Drug Monit. 1989; 11(3):228-30. DOI: 10.1097/00007691-198905000-00002. View

14.

Mandrioli R, Mercolini L, Saracino M, Raggi M . Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem. 2012; 19(12):1846-63. DOI: 10.2174/092986712800099749. View

15.

Johannessen S . Pharmacokinetics of valproate in pregnancy: mother-foetus-newborn. Pharm Weekbl Sci. 1992; 14(3A):114-7. DOI: 10.1007/BF01962699. View

16.

Scordo M, Spina E, Dahl M, Gatti G, Perucca E . Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol. 2005; 97(5):296-301. DOI: 10.1111/j.1742-7843.2005.pto_194.x. View

17.

Timmer C, Sitsen J, Delbressine L . Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000; 38(6):461-74. DOI: 10.2165/00003088-200038060-00001. View

18.

Werler M, Ahrens K, Bosco J, Mitchell A, Anderka M, Gilboa S . Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol. 2011; 21(11):842-50. PMC: 4816042. DOI: 10.1016/j.annepidem.2011.08.002. View

19.

Fotopoulou C, Kretz R, Bauer S, Schefold J, Schmitz B, Dudenhausen J . Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res. 2009; 85(1):60-4. DOI: 10.1016/j.eplepsyres.2009.02.011. View

20.

Heron J, Robertson Blackmore E, McGuinness M, Craddock N, Jones I . No 'latent period' in the onset of bipolar affective puerperal psychosis. Arch Womens Ment Health. 2007; 10(2):79-81. DOI: 10.1007/s00737-007-0174-z. View